AB
ABCL.US Abcellera Biologics Inc
- Market cap
- USD 3.80B
- P/E
- -
- P/B
- 3.67x
- ROE
- -17.5%
- Dividend yield
- -
- Fundamental score
- -
Ratios use the latest price and the current fiscal year annualized from 3 quarters up to Sep 2026.
Is ABCL.US undervalued?
Graham numberThe Graham number of Abcellera Biologics Inc cannot be estimated reliably (it needs positive earnings and book value).
Graham number = √(22.5 × EPS × book value per share): the most a defensive investor should pay according to Benjamin Graham. An estimate, not a recommendation to buy or sell. How is it calculated?
Abcellera Biologics Inc fundamental analysis
No fundamental analysis for Abcellera Biologics Inc yet.
Abcellera Biologics Inc stock price
Prices on the chart can differ slightly from the closing prices StockSummer uses for its ratios.
About Abcellera Biologics Inc
AbCellera Biologics Inc. engages in discovering and developing antibody-based medicines for indications with unmet medical need in the United States. Its lead product is ABCL635, an non-hormonal medicine, which is in Phase 2 clinical trial to treat moderate-to-severe vasomotor symptoms; and ABCL575, a fully human, half-life extended monoclonal antibody, which is in in a Phase 1 clinical trial for treating T-cell-mediated autoimmune conditions, such as atopic dermatitis. The …
Full company profileAbcellera Biologics Inc financial statements
2026 annualized: Fiscal year 2026 is not finished. Income statement and cash flow are annualized from 3 quarters up to Sep 30, 2026, the balance sheet is the latest quarter. Figures change when the annual report is published.
Abcellera Biologics Inc annual financial statements (USD; K = thousand, M = million, B = billion, T = trillion)
| Item | 2018 | 2019 | 2020 | 2021 | 2022 | 2023 | 2024 | 2025 | 2026 Anlz |
|---|---|---|---|---|---|---|---|---|---|
| Income Statement | |||||||||
| Revenue | 8.83M | 11.6M | 233M | 11.6M | 485M | 38.0M | 28.8M | 75.1M | 30.7M |
| Gross Profit | 8.83M | 11.6M | 206M | 11.6M | 419M | 38.0M | 28.8M | 46.3M | 19.1M |
| Operating Income | -753K | -4.12M | 156M | -4.12M | 217M | -237M | -315M | -217M | -231M |
| EBITDA | 1.44M | -155K | 170M | -155K | 260M | -192M | -204M | -149M | -169M |
| Net Income | 309K | -2.21M | 119M | -2.21M | 159M | -146M | -163M | -146M | -186M |
| EPS | 0.00 | -0.01 | 0.45 | -0.01 | 0.50 | -0.51 | -0.55 | -0.49 | -0.58 |
| Balance Sheet | |||||||||
| Total Assets | 21.5M | 23.5M | 1.01B | 1.32B | 1.54B | 1.49B | 1.36B | 1.36B | 1.50B |
| Total Liabilities | 9.88M | 13.2M | 175M | 293M | 308M | 336M | 304M | 390M | 437M |
| Shareholders' Equity | 11.6M | 10.3M | 831M | 1.03B | 1.23B | 1.15B | 1.06B | 967M | 1.06B |
| Cash & Short-term Investments | 10.4M | 7.55M | 594M | 723M | 886M | 761M | 626M | 534M | 764M |
| Total Debt | 3.44M | 6.89M | 6.78M | 40.1M | 82.3M | 77.4M | 65.4M | 143M | 134M |
| Cash Flow | |||||||||
| Operating Cash Flow | 3.57M | 2.69M | 22.7M | 245M | 277M | -43.9M | -109M | -131M | -54.0M |
| Capital Expenditure | 5.31M | 4.00M | 14.7M | 58.5M | 72.7M | 77.5M | 78.4M | 42.8M | 10.1M |
| Free Cash Flow | -1.74M | -1.30M | 8.02M | 186M | 205M | -121M | -187M | -174M | -64.1M |
| Ratios | |||||||||
| ROE | 2.7% | -21.6% | 14.3% | -0.2% | 12.9% | -12.7% | -15.4% | -15.1% | -17.5% |
| ROA | 1.4% | -9.4% | 11.8% | -0.2% | 10.3% | -9.8% | -12.0% | -10.8% | -12.4% |
| Net Profit Margin | 3.5% | -19.0% | 51.0% | -19.0% | 32.7% | -385.0% | -564.8% | -194.9% | -605.8% |
| Debt to Equity | 0.30x | 0.67x | 0.01x | 0.04x | 0.07x | 0.07x | 0.06x | 0.15x | 0.13x |
What these items mean
- Revenue
- Total sales of goods and services in the period.
- Gross Profit
- Revenue minus the direct cost of producing what was sold.
- Operating Income
- Profit from the core business after operating expenses.
- EBITDA
- Earnings before interest, taxes, depreciation and amortization.
- Net Income
- Profit left for shareholders after all expenses, interest and taxes.
- EPS
- Net income divided by shares outstanding.
- Total Assets
- Everything the company owns.
- Total Liabilities
- Everything the company owes.
- Shareholders' Equity
- Assets minus liabilities: the book value that belongs to shareholders.
- Cash & Short-term Investments
- Cash and investments that can be turned into cash quickly.
- Total Debt
- Short and long-term borrowings.
- Operating Cash Flow
- Cash generated by the core business.
- Capital Expenditure
- Cash spent on property, plant and equipment.
- Free Cash Flow
- Operating cash flow minus capital expenditure: cash left for dividends, buybacks or debt repayment.
- ROE
- Return on equity: net income divided by shareholders' equity.
- ROA
- Return on assets: net income divided by total assets.
- Net Profit Margin
- Net income as a share of revenue.
- Debt to Equity
- Total debt divided by shareholders' equity.
Abcellera Biologics Inc dividends
- Dividend yield
- -
- Forward dividend
- -
- Payout ratio
- -
- Ex-dividend date
- -
| Fiscal year | Dividends paid | Per share | Payout ratio |
|---|---|---|---|
| 2025 | - | - | - |
| 2024 | - | - | - |
| 2023 | - | - | - |
| 2022 | - | - | - |
| 2021 | - | - | - |
| 2020 | - | - | - |
| 2019 | USD 14.2K | 0.00 | - |
| 2018 | - | - | - |
From the cash flow statement: dividends paid in the fiscal year, divided by that year's shares outstanding. Payout ratio = dividends paid / net income.
Who owns Abcellera Biologics Inc
- Insiders 21.74%
- Institutions 36.80%
- Public & others 41.47%
- Shares outstanding 327M
- Free float 209M
Top funds holding ABCL.US
| Holder | Shares | % of shares | Change | As of |
|---|---|---|---|---|
| American Funds SMALLCAP World A | 13.2M | 4.08% | 0.00% | Sep 2026 |
| iShares Biotechnology ETF | 1.93M | 0.60% | -0.64% | Oct 2026 |
| ACATIS Datini Valueflex Fonds A | 1.86M | 0.57% | 0.00% | Sep 2026 |
| BlackRock Health Sciences Opps Inv A | 1.26M | 0.39% | 0.00% | Sep 2026 |
| Franklin Biotechnology Discv A(acc)USD | 1.00M | 0.31% | 0.00% | Sep 2026 |
| American Century Small Cap Growth Inv | 878K | 0.27% | 0.00% | Sep 2026 |
| UBS Lux Dgtl Hlth Eq Fd seeding P acc | 775K | 0.24% | -38.41% | Jul 2026 |
| iShares Genomics Immnlgy & Hlthcr ETF | 678K | 0.21% | 0.00% | Oct 2026 |
| DNB Fund Disrpt Opps A EUR Acc | 678K | 0.21% | +0.05% | Sep 2026 |
| Heptagon Driehaus US Micro Cap Eq C$ Acc | 617K | 0.19% | 0.00% | Sep 2026 |
| State Street® SPDR® Ptf Dev Wld exUS ETF | 582K | 0.18% | 0.00% | Oct 2026 |
| Franklin Biotechnology Discovery A | 537K | 0.17% | 0.00% | Sep 2026 |
| First Trust Dev Mkts Ex-US AlphaDEX® ETF | 432K | 0.13% | 0.00% | Oct 2026 |
| iShares Healthcare Innov ETF USD Acc | 373K | 0.12% | 0.00% | Oct 2026 |
| American Funds IS® SMALLCAP World 1 | 351K | 0.11% | -2.57% | Sep 2026 |
| Meridian Growth Legacy | 349K | 0.11% | 0.00% | Sep 2026 |
| iShares Nasdaq US Biotech ETF USD Acc | 277K | 0.09% | +0.20% | Oct 2026 |
| Fidelity Nasdaq Composite Index | 256K | 0.08% | +40.88% | Aug 2026 |
| Driehaus Micro Cap Growth USD | 247K | 0.08% | 0.00% | Sep 2026 |
| T. Rowe Price New Horizons | 164K | 0.05% | -83.11% | Sep 2026 |
Top institutions holding ABCL.US
| Holder | Shares | % of shares | Change | As of |
|---|---|---|---|---|
| Baker Bros Advisors LP | 33.0M | 10.19% | +9.04% | Jun 2026 |
| Capital World Investors | 13.6M | 4.19% | +1.70% | Jun 2026 |
| Two Sigma Investments LLC | 10.4M | 3.22% | -1.18% | Jun 2026 |
| TD Waterhouse Canada Inc | 9.57M | 2.95% | +0.04% | Jun 2026 |
| Bank of America Corp | 6.14M | 1.90% | +104.72% | Jun 2026 |
| UBS Asset Mgmt Americas Inc | 4.32M | 1.33% | -43.01% | Jun 2026 |
| ArrowMark Colorado Holdings, LLC (ArrowMark Partners) | 4.11M | 1.27% | 0.00% | Jun 2026 |
| BlackRock Inc | 3.81M | 1.17% | -5.81% | Jun 2026 |
| Driehaus Capital Management LLC | 2.86M | 0.88% | -28.82% | Jun 2026 |
| Tudor Investment Corp Et AL | 2.06M | 0.64% | -9.25% | Jun 2026 |
| Marshall Wace Asset Management Ltd | 1.90M | 0.59% | +428.85% | Jun 2026 |
| UBS Group AG | 1.87M | 0.58% | -55.56% | Jun 2026 |
| Morgan Stanley - Brokerage Accounts | 1.67M | 0.52% | -24.98% | Jun 2026 |
| T. Rowe Price Associates, Inc. | 1.59M | 0.49% | 0.00% | Jun 2026 |
| Citadel Advisors Llc | 1.59M | 0.49% | +16.56% | Jun 2026 |
| NATIONAL BANK OF CANADA /FI/ | 1.23M | 0.38% | +88,415.00% | Jun 2026 |
| Arrowstreet Capital Limited Partnership | 1.04M | 0.32% | 0.00% | Jun 2026 |
| Renaissance Technologies Corp | 991K | 0.31% | -34.40% | Jun 2026 |
| Counterpoint Mutual Funds, LLC | 972K | 0.30% | 0.00% | Jun 2026 |
| State Street Corp | 731K | 0.23% | +0.16% | Jun 2026 |
Abcellera Biologics Inc company profile
- Company name
- Abcellera Biologics Inc
- Ticker
- ABCL.US
- ISIN
- CA00288U1066
- Exchange
- USA Stocks
- Listed since
- Dec 11, 2020
- Sector
- Healthcare
- Industry
- Biotechnology
- Employees
- 562
- Fiscal year end
- December
- Address
- 150 W 4th Avenue, Vancouver, BC, Canada, V5Y 1G6
- Phone
- 604 559 9005
- Website
- abcellera.com
About Abcellera Biologics Inc
AbCellera Biologics Inc. engages in discovering and developing antibody-based medicines for indications with unmet medical need in the United States. Its lead product is ABCL635, an non-hormonal medicine, which is in Phase 2 clinical trial to treat moderate-to-severe vasomotor symptoms; and ABCL575, a fully human, half-life extended monoclonal antibody, which is in in a Phase 1 clinical trial for treating T-cell-mediated autoimmune conditions, such as atopic dermatitis. The company has a research collaboration and license agreement with Eli Lilly and Company; AbbVie Inc.; Jazz Pharmaceuticals plc to develop T-cell engaging (TCE) multispecific antibodies; partnership agreement with Viking Global Investors & ArrowMark Partners and Biogen Inc.; and Vertex Pharmaceuticals Incorporated to research, develop, manufacture, and commercialize multispecific T-cell engagers (TCEs) for autoimmune diseases and other conditions. AbCellera Biologics Inc. was incorporated in 2012 and is headquartered in Vancouver, Canada.
Abcellera Biologics Inc management
10- Dr. Carl L.G. Hansen Ph.D.CEO, President & Chairperson · born 1975
- Mr. Andrew Booth M.B.A.Chief Financial Officer · born 1974
- Dr. Veronique Lecault Ph.D.CTO & Director · born 1985
- Mr. Tryn T. Stimart Esq., J.D., M.Sc.Chief Legal Officer, Chief Compliance Officer, Corporate Secretary & Privacy Officer · born 1970
- Mr. Andrew Knowles M.Sc.Vice President of Operations
- Marcie Thiessen B.Com., CPA, CGASenior Director of Finance & Accounting
- Mr. Martin Hogan M.Sc.Senior Director of Strategic Finance & IR
- Ms. Tiffany Chiu B.Sc., Ph.D.Vice President of Communications
- Mr. Murray McCutcheon Ph.D.Senior Vice President of Partnering
- Mr. Adam Clarke M.A.I.C.D., Ph.D.Senior Vice President of Discovery